Clinical Trial Will Test Fluasterone in Cushing’s Syndrome

SteroTherapeutics and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) are teaming up to conduct a Phase 2 clinical trial to determine the safety, efficacy, and dosage regimen for fluasterone as a potential treatment for the metabolic manifestations of Cushing’s syndrome. “This…

Fluasterone Receives Orphan Drug Status for the Treatment of Hallmark Signs of Cushing’s Syndrome

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to fluasterone (ST-002) for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatosis, and high blood sugar in Cushing’s syndrome patients, SteroTherapeutics announced. Cushing’s syndrome occurs when the body is exposed to high levels of the hormone cortisol over a long period.

Mifepristone Improved Liver Condition Associated with Cushing’s Syndrome, Case Study Shows

The Cushing’s syndrome therapy mifepristone can alleviate a liver condition that often develops along with Cushing’s, a case study suggests. The disorder, which involves too many fat deposits in the liver, is called non-alcoholic fatty liver disease, or NAFLD. Researchers examined the case of a 49-year-old woman with Cushing’s syndrome and NAFLD…